Table 1.
Demographic and Clinical Profile of patients with skin and soft tissue infections.
| Total number of patients | N = 135 | ||
|---|---|---|---|
| Age (mean ± SD) | 27.7 ( ± 17.9) years | ||
| n (%) | |||
| Gender | Male | 64 (47.4%) | |
| Female | 71 (52.6%) | ||
| Clinical diagnosis | |||
| Cutaneous/subcutaneous abscess | 41 (30.4%) | ||
| Folliculitis/furuncle/impetigo | 35 (25.9%) | ||
| Secondary infection of underlying dermatological condition | 35 (25.9%) | ||
| Cellulitis | 14 (10.4%) | ||
| Wound infection | 10 (7.4%) | ||
| Recent antibiotic use | 24 (17.8%) | ||
| Antibiotics | n | ||
| Beta lactams | 10 | ||
| Fusidic acid | 6 | ||
| Fluoroquinolones | 2 | ||
| Unknown | 2 | ||
| Vancomycin, Mupirocin, Tetracycline, Erythromycin | n= 1 each | ||
| Recent travel history | 6 (4.4%) | ||
| Recent inset bite | 4 (2.9%) | ||
| Treatment with antibiotics | 66 (48.9%) | ||
| Antibiotics | n | ||
| Beta lactams | 36 | ||
| Fusidic acid | 15* | ||
| Macrolides | 10 | ||
| Mupirocin | 5** | ||
| Fluroquinolones | 4 | ||
| Tetracyclines | 4 | ||
| Staphylococcus aureus | Methicillin susceptible S. aureus (MSSA) | 86 (66.7%) | |
| identified (N=129) | Methicillin resistant S. aureus (MRSA) | 43 (33.3%) | |
| Outcome | Recovered | 135 (100%) | |
*6 patients received fusidic acid in combination with either a beta lactam, macrolide or tetracycline **2 patients received mupirocin in combination with a macrolide.